Abstract
Keratoconus is a progressive ectatic disorder characterised by irregular myopic astigmatism and loss of visual acuity due to corneal thinning. Corneal collagen crosslinking is the treatment recognised to stop the progression of keratoconus. Our study evaluates and compares visibility and depth of the stromal demarcation line after corneal collagen crosslinking using anterior segment optical coherence tomography between two groups:crosslinking with dextran-based and hydroxypropyl methylcellulose-based riboflavin solutions. Our work proved a better visibility and a deeper demarcation line when we used HPMC-based riboflavin. Also the study revealed that HPMC-based riboflavin is associated with better biomechanical outcomes than dextran-based riboflavin.
Highlights
Keratoconus is a progressive ectatic disorder characterised by irregular myopic astigmatism and loss of visual acuity due to corneal thinning and steepening[1]
Even if the use of riboflavin with dextran has been the gold standard in CXL procedures, it has a hyperosmolar effect, determining thinning of the cornea during the procedure and having a potential harmful effect for the endothelium[8,9]. riboflavin with hydroxypropylmetylcelluose was introduced as a solution that prevents thinning of the cornea during the CXL procedure
There were no significant differences between the two groups that were analyzed, in terms of their age, UDVA, CDVA, MRSE, astigmatism, Kmax, Kmin, pachymetry or corneal biomechanics parameters (CH, CRF, KMI)
Summary
Keratoconus is a progressive ectatic disorder characterised by irregular myopic astigmatism and loss of visual acuity due to corneal thinning. Malhotra et al compared the demarcation line depth after contact lens-assisted CXL using dextran-based and hydroxypropyl methylcellulose based riboflavin solutions. Results and discussions In the present study, a total of 60 eyes were analyzed, 30 in the dextran-based riboflavin group and 30 in the HPMC-based group.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
